MCID: CHR286
MIFTS: 44

Chronic Neutrophilic Leukemia

Categories: Rare diseases, Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Chronic Neutrophilic Leukemia

MalaCards integrated aliases for Chronic Neutrophilic Leukemia:

Name: Chronic Neutrophilic Leukemia 12 50 56 69
Leukemia Neutrophilic Chronic 52
Cnl 50

Characteristics:

Orphanet epidemiological data:

56
chronic neutrophilic leukemia
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0080187
NCIt 47 C3179
Orphanet 56 ORPHA86829
MESH via Orphanet 43 D015467
UMLS via Orphanet 70 C0023481
ICD10 via Orphanet 34 D47.1

Summaries for Chronic Neutrophilic Leukemia

Disease Ontology : 12 A chronic leukemia characterized by neutrophilic leukocytosis with no detectable Philadelphia chromosome or BCR/ABL fusion gene.

MalaCards based summary : Chronic Neutrophilic Leukemia, also known as leukemia neutrophilic chronic, is related to myeloproliferative neoplasm and leukemia. An important gene associated with Chronic Neutrophilic Leukemia is CSF3R (Colony Stimulating Factor 3 Receptor), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Jak-STAT signaling pathway (KEGG). The drugs Ketamine and Mycophenolate mofetil have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Wikipedia : 72 Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm that features a persistent... more...

Related Diseases for Chronic Neutrophilic Leukemia

Diseases related to Chronic Neutrophilic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
id Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 10.9
2 leukemia 10.6
3 neutropenia, severe congenital 3, autosomal recessive 10.4 CSF3 CSF3R
4 nephrolithiasis 10.4 ASXL1 CSF3R SETBP1
5 split hand/foot malformation x-linked 10.4 IFNA2 SETBP1
6 fetal nicotine spectrum disorder 10.4 ASXL1 CSF3R SETBP1
7 paranasal sinus disease 10.3 CD34 CSF3
8 male infertility 10.3 IFNA1 IFNA2
9 hemopneumothorax 10.3 CD34 IFNA2
10 breast ductal adenoma 10.3 IFNA1 IFNA2
11 malignant otitis externa 10.3 CD34 CSF3
12 primary cutaneous peripheral t-cell lymphoma not otherwise specified 10.2 ASXL1 CSF3 SETBP1
13 nuchal bleb, familial 10.2 IFNA1 IFNA2
14 enterovesical fistula 10.2 CSF3 IFNA1
15 spinocerebellar ataxia, autosomal recessive 21 10.1 CSF3 CSF3R KMT2A
16 myopia, autosomal 10.1 AFF1 KMT2A
17 aids wasting syndrome 10.1 IFNA1 IFNA2
18 thrombocythemia 3 10.1 CSF3R IFNA1 IFNA2
19 iridocyclitis 10.0 ASXL1 CD34
20 chronic myelomonocytic leukemia 10.0
21 nelson syndrome 9.9 CSF3 CSF3R IFNA1
22 polycythemia 9.9
23 congenital nystagmus 9.9 CSF3 IFNA1 IFNA2
24 myelodysplastic syndrome 9.9
25 multiple myeloma 9.9
26 acral lentiginous melanoma 9.9 CD34 IFNA1 IFNA2
27 hypertrophic elongation of cervix 9.8 IFNA2 XIAP
28 hypocalciuric hypercalcemia, type i 9.8 ASXL1 CD34 CSF3 CSF3R
29 peroxisome biogenesis disorder 5a 9.7 AFF1 CD34 KMT2A
30 myeloid leukemia 9.7
31 neutropenia 9.7
32 severe congenital neutropenia 9.7
33 atypical chronic myeloid leukemia 9.7
34 basilar artery insufficiency 9.7 ASXL1 CALR IFNA1 IFNA2
35 acute lymphoblastic leukemia, childhood 9.6 AFF1 CD34 CSF3 KMT2A
36 benign mammary dysplasia 9.6 CD34 CSF3 CSF3R IFNA1
37 nephrotic syndrome 9.6
38 cerebritis 9.6
39 tuberculosis 9.6
40 plasma cell neoplasm 9.6
41 amyloidosis 9.6
42 hemophilia a 9.6
43 miliary tuberculosis 9.6
44 cerebral hemorrhage 9.6
45 hemophilia 9.6
46 chronic lymphocytic leukemia 9.6
47 acquired hemophilia 9.6
48 acquired hemophilia a 9.6
49 cpt deficiency, hepatic, type ia 9.5 CD34 CSF3 IFNA1
50 smoking as a quantitative trait locus 1 9.3 BIRC3 CD34 CSF3 XIAP

Graphical network of the top 20 diseases related to Chronic Neutrophilic Leukemia:



Diseases related to Chronic Neutrophilic Leukemia

Symptoms & Phenotypes for Chronic Neutrophilic Leukemia

GenomeRNAi Phenotypes related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.78 IFNA1 IFNA2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.78 CSF3R
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.78 IFNA1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.78 CSF3R
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.78 IFNA2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.78 KMT2A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.78 CSF3R
8 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.78 CSF3R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.78 CSF3R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.78 IFNA1 IFNA2 KMT2A CSF3R
11 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.78 IFNA1 IFNA2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.78 CSF3R
13 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.78 KMT2A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.78 IFNA1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.78 IFNA2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.78 IFNA2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.78 IFNA1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.78 CSF3R
19 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.78 IFNA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.78 IFNA1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.78 IFNA1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.78 IFNA1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.78 IFNA1 KMT2A
24 Decreased viability after Chlamydia trachomatis serovar L2 infection and TNF-alpha/CHX stimulation GR00206-A 8.96 BIRC3 XIAP

MGI Mouse Phenotypes related to Chronic Neutrophilic Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.28 BIRC3 CAPNS1 CD34 CSF3 CSF3R KMT2A

Drugs & Therapeutics for Chronic Neutrophilic Leukemia

Drugs for Chronic Neutrophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 229)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 1,Phase 2 128794-94-5 5281078
3
Mycophenolic acid Approved Phase 3,Phase 1,Phase 2 24280-93-1 446541
4
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
5
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
6
Morphine Approved, Investigational Phase 3 57-27-2 5288826
7
Ephedrine Approved Phase 3 299-42-3 9294
8
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 22916-47-8 4189
9
Pseudoephedrine Approved Phase 3 90-82-4 7028
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
12
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
13
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
14
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
15
Norgestimate Approved Phase 3 35189-28-7 6540478
16
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
17 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
18 Analgesics Phase 3
19 Anesthetics Phase 3
20 Anesthetics, Dissociative Phase 3
21 Anesthetics, General Phase 3
22 Anesthetics, Intravenous Phase 3
23 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
24 Excitatory Amino Acid Antagonists Phase 3
25 Excitatory Amino Acids Phase 3
26 Neurotransmitter Agents Phase 3,Phase 2
27 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
28 Antirheumatic Agents Phase 3,Phase 2,Phase 1
29 Calcineurin Inhibitors Phase 3,Phase 2,Phase 1
30 Dermatologic Agents Phase 3,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
32 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
34 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
35 Bone Density Conservation Agents Phase 3,Phase 1,Phase 2
36 Calcium, Dietary Phase 3,Phase 1,Phase 2
37 Analgesics, Opioid Phase 3
38 Antitussive Agents Phase 3
39 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
40 Narcotics Phase 3
41 Respiratory System Agents Phase 3,Phase 2
42 Antifungal Agents Phase 3,Phase 1,Phase 2
43 Anti-Infective Agents Phase 3,Phase 1,Phase 2
44 Autonomic Agents Phase 3,Phase 2,Phase 1
45 Cyclosporins Phase 3,Phase 1,Phase 2
46 Nasal Decongestants Phase 3
47 Ophthalmic Solutions Phase 3,Phase 1,Phase 2
48 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
49 Tetrahydrozoline Phase 3,Phase 1,Phase 2
50 Vasoconstrictor Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 113)

id Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
3 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
4 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
5 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
6 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
7 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
8 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
9 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
10 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
11 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
12 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
13 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
14 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
15 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
16 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
17 Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
18 Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders Completed NCT00005622 Phase 2 cyclophosphamide
19 Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
20 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
21 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
22 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
23 Bone Marrow Transplant in Treating Patients With Hematologic Cancers Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
24 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
25 Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder Completed NCT00054340 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
26 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2 methylprednisolone;prednisone
27 Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant Completed NCT00530218 Phase 2 ganciclovir
28 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
29 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
30 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
31 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
32 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
33 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
34 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
35 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
36 Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Recruiting NCT02092324 Phase 2 Ruxolitinib Phosphate
37 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
38 Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders Active, not recruiting NCT00544115 Phase 2 busulfan;cyclophosphamide;cyclosporine;etoposide;fludarabine phosphate;melphalan;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus
39 Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer Active, not recruiting NCT00134017 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
40 Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease Terminated NCT00719849 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
41 Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
42 Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer Terminated NCT00295880 Phase 1, Phase 2
43 Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer Terminated NCT00281879 Phase 2 busulfan;carmustine;cyclophosphamide;cyclosporine;cytarabine;etoposide;fludarabine phosphate;melphalan;methotrexate;methylprednisolone;mycophenolate mofetil;tacrolimus
44 Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant Terminated NCT00617929 Phase 2 clofarabine
45 Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Withdrawn NCT00301912 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
46 Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer Withdrawn NCT00816413 Phase 1, Phase 2 cyclosporine;mycophenolate mofetil;pentostatin
47 Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
48 Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections Unknown status NCT00769613 Phase 1
49 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
50 Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders Completed NCT00357305 Phase 1 vorinostat;cytarabine;etoposide

Search NIH Clinical Center for Chronic Neutrophilic Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Chronic Neutrophilic Leukemia

Anatomical Context for Chronic Neutrophilic Leukemia

MalaCards organs/tissues related to Chronic Neutrophilic Leukemia:

39
Neutrophil, Bone, Bone Marrow, Myeloid, Liver, Eye, Kidney

Publications for Chronic Neutrophilic Leukemia

Articles related to Chronic Neutrophilic Leukemia:

(show top 50) (show all 127)
id Title Authors Year
1
Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. ( 28209656 )
2017
2
Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. ( 27789332 )
2017
3
Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. ( 28302714 )
2017
4
Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis. ( 28158286 )
2017
5
Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia. ( 28209919 )
2017
6
Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. ( 28762112 )
2017
7
Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. ( 27068405 )
2016
8
Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management. ( 26700908 )
2016
9
Chronic neutrophilic leukemia in a child with a CSF3R T618I germline mutation. ( 27581359 )
2016
10
Dao K-HT, Tyner JW. What's different about atypical CML and chronic neutrophilic leukemia? Hematology Am Soc Hematol Educ Program. 2015;2015:264-271. ( 27913552 )
2016
11
Genomics of chronic neutrophilic leukemia. ( 28028025 )
2016
12
A CSF3R T618I Mutation in a Patient with Chronic Neutrophilic Leukemia and Severe Bleeding Complications. ( 26875968 )
2016
13
A case of chronic neutrophilic leukemia successfully treated with pegylated interferon alpha-2a. ( 25983565 )
2015
14
Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: Clinical and molecular characterization. ( 25480691 )
2015
15
ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. ( 25850813 )
2015
16
Splenic rupture in primary amyloidosis with chronic neutrophilic leukemia. ( 25830123 )
2015
17
T618I-Mutated Colony Stimulating Factor 3 Receptor in Chronic Neutrophilic Leukemia and Chronic Myelomonocytic Leukemia Patients who Underwent Allogeneic Stem Cell Transplantation. ( 25932451 )
2015
18
Chronic neutrophilic leukemia: a clinical perspective. ( 26366092 )
2015
19
Sweet's syndrome associated with chronic neutrophilic leukemia. ( 25751350 )
2015
20
Chronic neutrophilic leukemia with overexpression of EVI-1, and concurrent CSF3R and SETBP1 mutations: A case report. ( 26622734 )
2015
21
What's different about atypical CML and chronic neutrophilic leukemia? ( 26637732 )
2015
22
Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. ( 25575036 )
2015
23
Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature review. ( 26137042 )
2015
24
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. ( 25498990 )
2014
25
Current strategies in the diagnosis and management of chronic neutrophilic leukemia. ( 25533830 )
2014
26
CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia. ( 25316523 )
2014
27
Chronic neutrophilic leukemia: a rare case report. ( 25332542 )
2014
28
Nephrotic syndrome related to chronic neutrophilic leukemia. ( 25366011 )
2014
29
Treatment of coexisting chronic neutrophilic leukemia and light chain multiple myeloma with hydroxyurea, bortezomib, and dexamethasone. ( 25143840 )
2014
30
Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. ( 24445868 )
2014
31
Chronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and management. ( 24845374 )
2014
32
Chronic Neutrophilic Leukemia with V617F JAK2 Mutation. ( 24839370 )
2014
33
CALR mutation studies in chronic neutrophilic leukemia. ( 24421250 )
2014
34
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. ( 25239264 )
2014
35
Chronic neutrophilic leukemia with plasma cell dyscrasia: friends or relatives? ( 23656197 )
2014
36
Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon I+-2b. ( 23391844 )
2013
37
CSF3R is mutated in chronic neutrophilic leukemia and atypical CML. ( 23847367 )
2013
38
Pregnancy in a woman with chronic neutrophilic leukemia. ( 23344408 )
2013
39
Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. ( 24203930 )
2013
40
CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia. ( 24212483 )
2013
41
Deletion of chromosome 17 as a novel cytogenetic finding in chronic neutrophilic leukemia: A case report. ( 23761837 )
2013
42
Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R. ( 24091926 )
2013
43
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. ( 23656643 )
2013
44
Plasma cell neoplasm associated chronic neutrophilic leukemia with membrane proximal and truncating CSF3R mutations. ( 24033109 )
2013
45
The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. ( 23896413 )
2013
46
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. ( 23604229 )
2013
47
Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation. ( 23248577 )
2012
48
Monoclonal gammopathy of undetermined significance disguised as chronic neutrophilic leukemia. ( 21415944 )
2010
49
Miliary tuberculosis associated with chronic neutrophilic leukemia. ( 19652431 )
2009
50
Chronic neutrophilic leukemia with congenital Robertsonian translocation successfully treated with allogeneic bone marrow transplantation in a young man. ( 19336960 )
2009

Variations for Chronic Neutrophilic Leukemia

Expression for Chronic Neutrophilic Leukemia

Search GEO for disease gene expression data for Chronic Neutrophilic Leukemia.

Pathways for Chronic Neutrophilic Leukemia

GO Terms for Chronic Neutrophilic Leukemia

Biological processes related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 defense response GO:0006952 9.61 CSF3R IFNA1 IFNA2
2 B cell proliferation GO:0042100 9.51 IFNA1 IFNA2
3 response to exogenous dsRNA GO:0043330 9.49 IFNA1 IFNA2
4 regulation of type I interferon-mediated signaling pathway GO:0060338 9.48 IFNA1 IFNA2
5 T cell activation involved in immune response GO:0002286 9.46 IFNA1 IFNA2
6 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.4 IFNA1 IFNA2
7 natural killer cell activation involved in immune response GO:0002323 9.37 IFNA1 IFNA2
8 regulation of innate immune response GO:0045088 9.32 BIRC3 XIAP
9 negative regulation of retinoic acid receptor signaling pathway GO:0048387 9.26 ASXL1 CALR
10 cytokine-mediated signaling pathway GO:0019221 9.26 CSF3 CSF3R IFNA1 IFNA2
11 inhibition of cysteine-type endopeptidase activity involved in apoptotic process GO:1990001 9.16 BIRC3 XIAP
12 regulation of nucleotide-binding oligomerization domain containing signaling pathway GO:0070424 8.62 BIRC3 XIAP

Molecular functions related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.16 IFNA1 IFNA2
2 cysteine-type endopeptidase inhibitor activity involved in apoptotic process GO:0043027 8.96 BIRC3 XIAP
3 type I interferon receptor binding GO:0005132 8.62 IFNA1 IFNA2

Sources for Chronic Neutrophilic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....